

Vertical and horizontal guided bone regeneration (GBR) using a Ti-reinforced non-resorbable e-PTFE membrane and simultaneous implant placement. A retrospective study

Nicolas Hassfurther^{1,2}, Norbert Hassfurther¹

¹ Private Practice, Wettenberg, Germany

² Faculty of Medicine, Justus Liebig University Giessen, Giessen, Germany

This retrospective chart review of 903 sites treated according to a GBR protocol with simultaneous implant placement using NeoGen PTFE membranes and Neoss ProActive implants showed an implant survival rate of 99.8% after a follow-up of up to 5 years after membrane removal. Vertical ridge augmentation cases showed a mean bone fill of 86% Membrane related soft tissue complications occurred in 11% of the cases.

INTRODUCTION

Guided bone regeneration (GBR) is a treatment concept for bone augmentation where a membrane is placed between the soft tissue and the bone, to obstruct the soft tissue from growing into the bone defect. The membrane creates a space where the bone forming cells can generate new bone without the interference from soft tissue cells.

GBR can be performed in numerous ways: with resorbable or non-resorbable membranes, with or without grafting material, with or without structural reinforcement, in a staged approach or simultaneous with implant placement.²

The aim of the study was to retrospectively study the clinical outcome of a GBR procedure using a Ti-reinforced non-resorbable e-PTFE membrane and autogenous bone material with simultaneous implant placement. Results from this study cohort has previously been published.^{1,2}

MATERIALS AND METHODS

Study design

This retrospective study reports on the clinical outcome of consecutive patients treated in the same clinic by one surgeon (NoH) using a surgical protocol where a guided bone regeneration (GBR) procedure using autogenous bone

material and a non-resorbable e-PTFE membrane (NeoGen Ti-Reinforced PTFE Membrane, Neoss, Gothenburg, Sweden) was performed at time of implant placement.


All patients that underwent the clinical procedure were deemed appropriate through clinical and radiographic examination before treatment. The patients were informed of the procedures and gave their written consent before treatment.

All study data was collected through a retrospective chart review. All collected data was part of the patients files, therefore no additional treatments were performed as part of this study. The retrospective data collection was conducted in accordance with the World Medical Association Declaration of Helsinki and approved by the Ethics Committee of the Department of Medicine of the Justus Liebig University Giessen (AZ 222/19).

Treatment protocol

Antibiotic treatment was commenced the evening before surgery and lasted for 5 days. All surgeries were performed under local anesthesia.

A full thickness flap with releasing incisions was opened and the implant site was prepared (Figure 1B).



Implant osteotomies were drilled according to the manufacturer's guidelines to achieve good primary stability.

Autogenous bone chips were collected during preparation of the implant osteotomies using a bone collecting device connected to the suction system.

One or more dental implants (Neoss ProActive Straight, Neoss, Sweden) were placed with the implant-abutment connection at planned future bone level and a cover screw was connected (Figure 1C–D).

In larger defect cases, autogenous bone cylinders were used together with the autogenous bone chips to accelerate regeneration and to act as space fillers (Figure 1E–F). The bone cylinders (height up to 5 mm) were harvested from the oblique line of the mandible in the molar region using a 3.4 mm trephine drill. In smaller defect cases, only autogenous bone chips were used. No additional bone substitutes were used.

A Ti-reinforced e-PTFE membrane (NeoGen Ti-Reinforced PTFE Membrane, Neoss, Gothenburg, Sweden) was trimmed, shaped (Figure 1G), and fitted at the surgical site and secured buccally using membrane tacks (Figure 1H–I). A stable membrane configuration was achieved using the implants as tent posts.

Stress free flap closure was achieved by releasing the periosteum on the buccal side (Figure 1J).

The augmented sites were typically allowed to heal for 4–7 months, depending on clinical situation. After the healing period, second stage surgery was performed. A mid-crestal incision with releasing incisions was used. The flap was lifted to expose the membrane (Figure 1K) and the membrane was removed. If needed, excess bone on top of the cover screw (Figure 1L) was removed to get access to the implant. PEEK healing abutments (Neoss, Sweden) were connected to the implants for transgingival healing (Figure 1M) and the flap was closed (Figure 1N).

The definitive prostheses were delivered 0–18 months (average 2.8 months) after membrane removal.

Baseline parameters

Baseline parameters (age, gender, smoking habits, diabetes, tooth status, defect type, type of bone transplant, bone quality, and primary stability) were retrieved from the patient files (Table 1).

Follow-up

All information on membrane complications, such as infection and membrane exposure, were compiled from the patient records. The influence of the recorded baseline parameters on complication rate was evaluated.

| Parameter | Group | n | % |
|-------------------------|-----------------------------------|-----|------|
| Gender | Female | 322 | 50.1 |
| | Male | 321 | 49.9 |
| Age | 10–19 | 11 | 1.7 |
| | 20–29 | 19 | 3.0 |
| | 30–39 | 37 | 5.8 |
| | 40–49 | 77 | 12.0 |
| | 50–59 | 207 | 32.2 |
| | 60–69 | 189 | 29.4 |
| | 70–79 | 95 | 14.8 |
| | 80–89 | 7 | 1.1 |
| | 90–99 | 1 | 0.2 |
| Smoker | No | 496 | 77.1 |
| | Yes | 147 | 22.9 |
| Diabetes | No | 628 | 97.7 |
| | Yes | 15 | 2.3 |
| Defect type | Fenestration defect | 36 | 5.6 |
| | Intra-alveolar defect | 12 | 1.9 |
| | Horizontal defect < 50% | 217 | 33.8 |
| | Horizontal defect > 50% | 254 | 39.5 |
| | Horizontal defect buccal and oral | 24 | 3.7 |
| | Vertical defect ≤ 3 mm | 62 | 9.6 |
| | Vertical defect > 3 mm | 38 | 5.9 |
| Tooth status | Edentulous jaw | 29 | 4.5 |
| | Free-end gap | 166 | 25.8 |
| | Single-tooth gap, anterior | 131 | 20.4 |
| | Single-tooth gap, posterior | 133 | 20.7 |
| | Interdental gaps, anterior | 49 | 7.6 |
| | Interdental gaps, posterior | 121 | 18.8 |
| | Reduced residual dentition | 14 | 2.2 |
| Type of bone transplant | None | 4 | 4.0 |
| | Bone chips | 34 | 34.3 |
| | Bone cylinders | 12 | 12.1 |
| | Bone chips + Bone cylinders | 49 | 49.5 |
| Bone quality | D1 | 120 | 18.7 |
| | D2 | 194 | 30.2 |
| | D3 | 150 | 23.3 |
| | D4 | 179 | 27.8 |
| Primary Stability | High (> 30 Ncm) | 448 | 69.7 |
| | Poor (8–30 Ncm) | 154 | 24.0 |
| | Spinner (< 8 Ncm) | 39 | 6.1 |
| | None (extraaxial movement) | 2 | 0.3 |

Table 1: Baseline parameters

The latest time-point registered in the patient's file was used for the implant follow-up. Implant follow-up time was calculated from time of membrane removal.

Vertical ridge augmentation

In sites where vertical ridge augmentation was performed ($n = 95$), the vertical bone level was assessed at time of surgery and at membrane removal. The change in bone level as well as the percentage bone gain was assessed (0% = no bone gain, 100% = bone regenerated to level of implant platform). One implant from each augmentation was chosen for analysis.

| Parameter | All sites | Vertical ridge augmentation sites |
|------------------------------------|-----------|-----------------------------------|
| Number of implants | 903 | 95 |
| Early exposure rate | 7% | 11% |
| Infection rate | 4% | 10% |
| Overall membrane complication rate | 11% | 21% |
| Implant restorability rate | 100% | 100% |

Table 2: Membrane complication rates**RESULTS***Overall outcome*

The chart review identified 903 sites where a GBR procedure using a NeoGen PTFE membrane was performed simultaneous with implant placement. Vertical ridge augmentation was performed in 95 of these sites.

Eleven percent (11%) of the membrane sites experienced complications that required intervention, 7% were early exposures and 4% were infections. The corresponding complication rates in vertical ridge augmentations was slightly increased, 11% and 10% respectively (Table 2). Although some membranes had to be removed early, all placed implants could be restored. One implant failed after 2 years, resulting in an cumulative implant survival rate of 99.8% (Table 3).

| Time interval | Implants | Failed | Withdrawn / Not followed | CSR |
|------------------|----------|--------|--------------------------|-------|
| Insert. – 1 year | 903 | 0 | 332 | 100% |
| 1 – 2 years | 571 | 0 | 139 | 100% |
| 2 – 3 years | 432 | 1 | 194 | 99.8% |
| 3 – 4 years | 237 | 0 | 166 | 99.8% |
| 4 – 5 years | 71 | 0 | 67 | 99.8% |
| 5 years | 4 | – | – | – |

Table 3: Life table analysis. Dental implant survival.*Vertical ridge augmentation*

The mean vertical defect size at surgery was 3.9 ± 2.3 mm, measured with the implant as reference. After augmentation the mean marginal bone level was 0.5 ± 0.9 mm. This represents a mean bone gain of 87.5%. Bone regeneration up to or above the implant platform was achieved in 51% of the sites.

Evaluation of risk factors

For three parameters (defect type, tooth status and smoking) there was a significant impact on complication rate. The impact of each parameters as well as a proposed risk classification is given in Table 4. For all other investigated parameters, there was no significant difference in complication rate between groups, and thus not considered risk factors for the procedure.


| | Low risk | | Decreased risk | | Increased risk | | High risk |
|--|---|---|-----------------------------------|---|-----------------------------------|----------------------------------|----------------------------|
| Defect type |  | | | | | | |
| | Fenestration defect | Horizontal defect < 50% of the implant length | Intra-alveolar defect | Horizontal defect > 50% of the implant length | Horizontal defect buccal and oral | Vertical defect ≤ 3 mm | Vertical defect > 3 mm |
| Risk ratio | 0.4 | 0.8 | 0.9 | 1.2 | 1.6 | 1.6 | 2.4 |
| Tooth status | Edentulous jaw | Free-end gap | Single-tooth gap posterior region | Interdental gaps posterior region | Single-tooth gap anterior region | Interdental gaps anterior region | Reduced residual dentition |
| Risk ratio | 0.5 | 1.0 | 1.1 | 1.3 | 1.3 | 1.6 | 1.7 |
| Smoking | Non-smoker | | | | | Smoker | |
| Risk ratio | 0.9 | | | | | 1.4 | |
| Examples: Based on an average risk of 11% in the population | A non-smoking patient with a small horizontal defect in the toothless-jaw has a risk of membrane complication of 4%: (11% × 0.8 × 0.5 × 0.9 = 4%) A smoking patient with a large vertical defect with reduced residual dentition has a risk of membrane complication of 63%: (11% × 2.4 × 1.7 × 1.4 = 63%) | | | | | | |

Table 4: Risk classification for e-PTFE membrane complication in relation to average risk.

DISCUSSION

In the present study, membrane complications occurred in 11% of the membrane sites. This is well in line with what is reported in a recent systematic review by Lim et al that reported an average complication rate of 17.6% for non-resorbable membranes and 18.3% for resorbable membranes.³

Membrane complications do occur, but it is not an event that automatically result in a failed treatment. On the contrary, all complications in the present study were resolved and all implants could be restored. This is in line with the results of Lim et al. They reported that the majority of studies in their systematic review achieved complete healing of the sites that had experienced complications without significant impact on the bone augmentation procedure.³

The risk classification given in Table 4, shows how different parameters influence the risk of complications. It should not be used as a formula to calculate exact risk ratios, but more as a tool to see how combining different indications and parameters can lead to higher risk and thereby identifying if a patient is at risk for the procedure.

It is concluded that guided bone regeneration (GBR) using the Ti-reinforced NeoGen PTFE membrane and simultaneous implant placement is a reliable and time efficient treatment in cases where bone augmentation is needed for implant placement.

REFERENCES

1. Dahlin C, Linde A, Gottlow J, Nyman S. Healing of bone defects by guided tissue regeneration. *Plast Reconstr Surg*. 1988;81:672-676
2. Retzepi M, Donos N. Guided Bone Regeneration: biological principle and therapeutic applications. *Clin Oral Implants Res*. 2010;21:567-576
3. Lim G, Lin GH, Monje A, Chan HL, Wang HL. Wound Healing Complications Following Guided Bone Regeneration for Ridge Augmentation: A Systematic Review and Meta-Analysis. *Int J Oral Maxillofac Implants*. 2018;33:41-50